CORE--BIOIMAGING FACILITY

1998年底，癌症中心将两个核心基金资助的共享资源（成像设备和共聚焦显微镜核心）与医学院支持的电子显微镜核心整合在一起，电子显微镜核心一直是美国国立卫生研究院长期资助的糖尿病和内分泌学研究中心的一部分。重组和重新定义这些核心的目标是创建一个更具成本效益、利用率更高、最先进的共享资源。这个新的、重组和扩展的设施被命名为“生物医学成像中心”。生物医学成像核心由Leonard Jarett医学博士领导，他曾担任病理学和实验室医学主席18年，直到1998年卸任。Jarett博士创立并指导电子显微镜核心近20年。考虑到通过非核心基金获得的技术先进设备以及设施和技术总监和工作人员的专家能力，癌症中心认为，新的，重组的生物医学成像核心将是nci资助的重要共享资源在下一个项目期间。根据对癌症中心成员的一项调查，对将提供的服务有很大的需求。这项调查向执行委员会提供了进一步的证据，证明重组后的核心将为支持癌症中心大量成员开展的创新研究项目提供重要的资源和服务。据预测，获得同行评审资助的癌症中心成员的使用量将占总使用量的40%。所有癌症中心成员的使用量预计为总使用量的50%。

In late 1998, the Cancer Center integrated two Core Grant-funded Shared Resources (Imaging Facility and Confocal Microscopy Core) with a School of Medicine-supported Electron Microscopy Core, which continues to be a part of a long-standing NIH-funded Diabetes and Endocrinology Research Center. The goal of the reorganization and redefinition of these cores was to create a more cost-effective, highly utilized, state-of-the-art Shared Resource. This new, reorganized and expanded facility has been named "Biomedical Imaging Core." The Biomedical Imaging Core is directed by Leonard Jarett, MD, who served as Chair of Pathology and Laboratory Medicine for 18 years until stepping down in 1998. Dr. Jarett founded and has directed the Electron Microscopy Core for nearly twenty years. Given the technologically advanced equipment which has been acquired through non-Core Grant funds as well as the expert capabilities of the Facility and Technical Directors and staff, the Cancer Center believes that the new, reorganized Biomedical Imaging Core will be an important NCI-funded Shared Resource during the nest project period. Based on a survey to Cancer Center members, there is significant demand for the services that will be offered. This survey gave further evidence to the Executive Committee that the reorganized core will provide important resources and services that are needed to support the innovative research projects conducted by a significant number of Cancer Center members. It is projected that usage by Cancer Center members with peer reviewed funding will be 40% of total usage. Usage by all Cancer Center members is expected to be 50% of total usage.